FindTrial
Sign In

The role of hepcidin in predicting and conducting iron supplement for anemia in maintenance hemodialysis patients

The role of hepcidin in predicting and conducting iron supplement for anemia in maintenance hemodialysis patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DDD-17010847
Enrollment
Unknown
Registered
2017-03-12
Start date
2017-04-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End stage renal disease

Interventions

Gold Standard:End stage renal disease (ESRD) patients, who are undergoing dialysis and have anemia.
Index test:serum hepcidin

Sponsors

Xuzhou Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: ? The hemodialysis patients in the blood purification center of Xuzhou Central Hospital, the course of hemodialysis =3 months ? Willing to participate in this clinical trial and signed the informed consent.

Exclusion criteria

Exclusion criteria: ? Refusing to participate in this clinical trial.

Design outcomes

Primary

MeasureTime frame
All-cause mortality;cardiovascular events;Infection events;—

Countries

China

Contacts

Public ContactLing Sun

Xuzhou Central Hospital

slpku@163.com+86 0516-83956890

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026